Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorGoto, Y.
dc.contributor.authorLim, W. D. T.
dc.contributor.authorHalmos, B.
dc.contributor.authorCho, B. C.
dc.contributor.authorDols, M. Cobo
dc.contributor.authorGonzalez-Larriba, J. L.
dc.contributor.authorZhou, C.
dc.contributor.authorDemedts, I.
dc.contributor.authorAtmaca, A.
dc.contributor.authorBaka, S.
dc.contributor.authorMookerjee, B. P.
dc.contributor.authorPortella, S.
dc.contributor.authorZhu, Z.
dc.contributor.authorDharan, B.
dc.contributor.authorReck, M.
dc.contributor.authoraffiliation[Paz-Ares, L.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Goto, Y.] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
dc.contributor.authoraffiliation[Lim, W. D. T.] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
dc.contributor.authoraffiliation[Halmos, B.] Albert Einstein Coll Med, Montefiore Med Ctr, New York, NY USA
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ Hlth Syst YUCM, Seoul, South Korea
dc.contributor.authoraffiliation[Dols, M. Cobo] Carlos Haya Reg Univ Hosp Malaga, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Gonzalez-Larriba, J. L.] Clin San Carlos Univ Hosp, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Zhou, C.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
dc.contributor.authoraffiliation[Demedts, I.] AZ Delta Hosp, Roeselare, Belgium
dc.contributor.authoraffiliation[Atmaca, A.] Univ Canc Ctr UCT, Frankfurt, Germany
dc.contributor.authoraffiliation[Baka, S.] European Interbalkan Med Ctr, Thessaloniki, Greece
dc.contributor.authoraffiliation[Mookerjee, B. P.] Novartis Pharmaceut, Oncol Clin Dev, E Hanover, NJ USA
dc.contributor.authoraffiliation[Portella, S.] Oncol Clin Dev, Novartis Pharmaceut Corporat, E Hanover, NJ USA
dc.contributor.authoraffiliation[Zhu, Z.] Novartis Pharmaceuticals Corp, Oncol Global Dev, E Hanover, NJ USA
dc.contributor.authoraffiliation[Dharan, B.] Novartis Pharmaceuticals Corp, Oncol Global Dev, E Hanover, NJ USA
dc.contributor.authoraffiliation[Reck, M.] Airway Res Ctr North ARCN, German Ctr Lung Res DZL, LungenClin, Grosshansdorf, Germany
dc.contributor.funderNovartis
dc.date.accessioned2025-01-07T12:22:35Z
dc.date.available2025-01-07T12:22:35Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1799
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1799
dc.identifier.urihttps://hdl.handle.net/10668/24516
dc.identifier.wosID700527702213
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS953-S954
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleCanakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía